Operator
Operator
Good morning, ladies and gentlemen, and welcome to the Church & Dwight First Quarter 2015 Earnings Conference Call. Before we begin, I have been asked to remind you that on this call, the company's management may make forward-looking statements regarding, among other things, the company's financial objectives and forecasts. These statements are subject to risks and uncertainties and other factors that are described in detail in the company's SEC filings. I would now like to introduce your host for today's call, Mr. Jim Craigie, Chairman and Chief Executive Officer of Church & Dwight. Please go ahead, sir. James R. Craigie - Chairman & Chief Executive Officer: Good morning, everyone. It's always a pleasure to talk to you, particularly when we have great results to report. I'll start off this call by providing you with my perspective on our first quarter business results, which you've read about in our press release this morning. I'll then turn the call over to Matt Farrell, our Chief Financial Officer and Chief Operating Officer. Matt will provide you with his perspective on the financial details for the quarter. When Matt is finished, I'll return to discuss our earnings guidance for the year and then we'll open the call to field questions from you. Let me start off by saying that I'm very proud of my company for the first quarter business results that we achieved. Despite headwinds from continued weak U.S. consumer demand and foreign currency, the Church & Dwight team built upon our momentum exiting 2014 and continued to leverage our innovation-driven strategy to deliver strong business results in the first quarter of 2015. As I have stated in our previous earnings release and at the CAGNY Conference in February, we believe that innovation is the key to delivering strong sales and earnings growth in any economic and competitive environment. Innovation has been a key driver of our past success, as shown by the fact that over one-third of our sales in 2014 came from new products launched since 2007. In 2014, we launched a record number of innovative new products across every one of our major categories and three new categories. In 2015, we launched fewer new products, but our new products covered every major category. Some of these new products like our new premium priced cat litter called ARM & HAMMER CLUMP & SEAL, have become a huge hit with our consumers as reflected in both our brand share results and its impact on category growth. In 2014, our cat litter consumption increased by 23.5% and our share grew by 2.9 points to a record share of 22.9%. This enabled our brand to move from the number three brand in the category to a strong and growing number two brand. Just as important, our new product has been a major contributor to driving an 8% increase in the cat litter category in 2014, the strongest annual growth in any of our categories and excellent growth for any CPG category. This exemplifies our belief that innovation is the key anecdote for driving improved value-creation for our consumers, our customers and our shareholders. In the first quarter of 2015, we built upon this success by launching a new light-weight version of the CLUMP & SEAL cat litter. This new product is also off to a great start. Our total ARM & HAMMER cat litter consumption in the first quarter was up 15.5% and our share grew 1.4 points to a new record share of 23.8%. And this growth helped drive the cat litter category up 8.6% in the first quarter over the first quarter of last year. Our goal is to continue launch innovative new products to drive share gains and category growth like this in all of our categories in which we compete. Overall, the first quarter results were excellent on the share front, with share growth on three of our four megabrands. I'll now turn the call over to Matt, to give you specific details on our first quarter results. Matthew Thomas Farrell - Executive VP, Chief Operating & Financial Officer: Thank you, Jim. Good morning, everybody. I'm going to start with EPS. So, first quarter EPS was $0.80 per share; that compares with $0.73 last year in the first quarter, so we're up 9.6%. The $0.80 was better than our $0.78 outlook, and netted in our $0.80 is $0.03 or a 4% drag from FX year-over-year. So we're off to a very good start in 2015. Reported revenues were up 3.9% to $812 million. Organic sales for the quarter was 3.6% and this exceeded our Q1 outlook of 3% organic sales. The organic sales beat was largely driven by the success of our international business and the continued strength of our animal nutrition business. Of the 3.6% organic growth, approximately 3.2% is volume-driven with 40 bps of positive product mix and price. Now, we're going to go through the segments. The Consumer Domestic business' organic sales increase was 1.6%, and that was in line with our expectations, and was driven by ARM & HAMMER CLUMP & SEAL cat litter, VITAFUSION adult vitamins, and ARM & HAMMER liquid laundry detergent. Now these increases were partially offset by lower sales of XTRA laundry detergent, TROJAN condoms, and OXI laundry detergent. Remember last year, we had the launch of OXI laundry detergent in the first quarter. So the 1.6% met our expectations; we were lapping the new product pipeline from last year. It was our largest year ever of innovation in Q1. The volume growth contributed approximately 1.2% to organic sales, plus 40 bps effect of positive price net of negative mix in the quarter. We expect full year organic sales to be approximately 2% to 3% for our Consumer Domestic business, and notably in the second quarter, we expect 3% to 4% organic growth from domestic. Now we're going to talk about International. International organic growth was up 9.5%, volume contributed 10.5% with product mix and pricing being a drag of 1%. We had strong growth in France, the UK, Mexico and our export business, largely driven by two brands, Batiste and Sterimar, which is our nasal hygiene brand. We expect the full year to be approximately 3% to 4% organic for the Consumer International business. And now turning to Specialty Products, organic sales for the Specialty Products division increased 10.8%. The animal nutrition business drove a 7.7% volume increase and we also had favorable mix and pricing of 3.1%. With respect to the Animal Nutrition business, currently, the U.S. dairy industry is still healthy, driven by demand for our products – driving demand for our products, I should say. We expect organic sales for this division to come back down to earth for the balance of the year. We have very difficult comps ahead of us for this division. Remember last year in Q2, Q3 and Q4, we grew 20% year-over-year in each of those three quarters. So, for the full year, we expect the Specialty Products business to be up 3% to 4% organically. So now, total company, full year, we expect organic sales to be approximately 3%. And you saw that in the release. Gross margin is next. Our reported first quarter gross margin was 43.8%. That's 40 bps better than last year. If we look at it year-over-year, 20 bps came from volume and price and the other 20 bps is the net of higher margin acquired businesses net of FX drag. The company's outperformance versus the outlook, remember that our outlook was flat gross margins for the quarter, our outperformance was due to higher-than-expected volumes, earlier-than-expected benefit from commodities, and some of the start-up costs related to our new vitamin plant have moved to the second quarter. For the full year, remember in February we called 25 basis points of gross margin expansion. Now, we have 40 basis points of a beat in Q1, so that's going to live through for the year and that's what's driving the change in our gross margin, the 25 to 35 basis points on a full-year basis. Now I'm going to talk about marketing. Marketing spend for the first quarter was $88.8 million or 10.9% of revenues, that's 30 basis points lower than the prior year's spend rate, but it's $1 million higher on a dollar spend. Marketing is a function of the timing of our product launches, as you know, and our full-year expectation is still approximately 12.5% of sales. Next is SG&A. So SG&A as a percentage of net sales was 11.7% in Q1; that's a 20-basis-points increase from the prior-year first quarter. That's primarily driven by incremental amortization of intangibles and higher R&D costs. On a full-year basis, we still expect 15 basis points improvement year-over-year in SG&A as a percentage of sales. Other income is next. So other income was $9.1 million negative, that's $2.2 million worse than the prior year. And that's primarily driven by transaction FX. And next is operating profit. The reported operating margin for the quarter was 21.2%, which is 50 bps higher than the prior year first quarter. With respect to income taxes, our effective rate for the quarter is 35.1%. And that's higher than our full-year expectation of 34.5%. The tax rates in the quarters can be lumpy, but we continue to expect the full-year 2015 effective tax rate to be approximately 34.5%. Cash is next. So we generated $144 million of net cash from operations in the first three months of the year and we invested approximately $22 million in CapEx year-to-date. That's a big number for a first quarter, but remember we were wrapping up construction of our new vitamin plant in York, Pennsylvania. We expect to spend approximately $70 million on a full-year basis on CapEx in 2015. Cash from operations is expected to exceed $570 million and free cash flow to exceed $500 million. We bought back $250 million of shares in Q1. That's right on target with what we said in February. And remaining on our share repurchase authorization is approximately $332 million. Just a word on the new vitamin plant. As you read in the release, we are starting up our new vitamin plant. We have been living hand-to-mouth for a number months as demand has exceeded our capacity. And the new plant is expected to expand our capacity by 75%. And the future prospects for this business are very bright as more adults switch to gummy vitamins. I'm going to wrap it up now. So, the first quarter highlights include 3.6% organic sales growth; 9.6% EPS growth, which, by the way, equates to 13.6% currency neutral EPS growth. Thinking ahead to Q2, we expect second quarter earnings per share of approximately $0.70 compared to $0.65 last year. So, that's 8% up year-over-year in Q2. And that excludes a pension termination charge of about $0.05 that we expect to occur in the second quarter, and we've been talking about that one for a while. We expect Q2 organic sales growth of approximately 3% to 4% and flat gross margin. With respect to flat gross margin, that reflects our greater vitamin plant start-up cost shifting to Q2, as I mentioned earlier, and the negative drag of FX, and also further investment in OxiClean in the second quarter. And the commodity relief is going to be as expected for Q2. Now the full-year. So, last year we had all of our EPS growth in the second half of the year. So, 2014 was a back-end loaded year from an earnings perspective. This year we have higher organic and EPS growth in the first half due to easier comps, and our most difficult revenue and EPS comps are ahead of us in the third or fourth quarter. With respect to the full year, just to bomb down the income statement, 3% organic sales, a gross margin expansion of 25 to 35 bps, marketing at 12% of sales, and 15 basis points of leverage on SG&A. So that math gets us to operating margin expansion of 50 to 60 bps in 2015. And to the extent we over perform on gross margin expansion, and we intend to invest incrementally in marketing behind our megabrands. One thing I missed was other income and expense. It's going to be relatively flat year-over-year, about $17 million of net expense. And the full year range remains at 7% to 9%, that's despite a 3% drag from currency. We used to think it was going to be 2.5%, so it's got a little bit worse. Back to you now, Jim. James R. Craigie - Chairman & Chief Executive Officer: Thanks, Matt. Before I open the floor to questions, I'd like to provide a few highlights on our first quarter business results in our key categories and business units. As you know, we continue to sharpen our focus in our four megabrands, ARM & HAMMER, OxiClean, Trojan, and our vitamin business. These four brands represent over 60% of our company's sales and profits, and we have achieved the most growth over the past five years due to delivering a bigger bang for every dollar of marketing investment. In 2015, we plan to spend over 80% of our media investment on these four megabrands. This investment continues to pay off as reflected in my earlier statement that we achieved share growth on three of these four megabrands in the first quarter. The ARM & HAMMER megabrand had an excellent quarter, with total consumption up 4.3% driven by its laundry detergent and cat litter products. I previously mentioned cat litter results in which consumption grew 15.5% in the first quarter and our share increased 1.4 percentage points to a record 23.8% share behind the new CLUMP & SEAL product line. ARM & HAMMER laundry detergent also had a solid quarter growth. While the total laundry detergent category was down 1.3% versus a year ago, the rate of decline has steadily improved for past four quarters. Hopefully, this category will soon begin to generate positive growth again driven by innovations and the return to a more historical promotional environment. In the first quarter, ARM & HAMMER liquid laundry detergent achieved a 10.0% share, up 0.5 percentage points versus year ago, the 21st consecutive quarter of year-on-year share growth. As a total company, Church & Dwight achieved a 14.1% dollar share of total detergents in the first quarter, up 0.6 percentage points versus year ago. We have grown share year-on-year in the laundry detergent category in 19 of the past 20 quarters. And we're one of only two manufacturers in the category to post dollars sales growth and share growth in the first quarter. We do not often talk about other products and all the categories covered by the ARM & HAMMER megabrand, but ARM & HAMMER carpet deodorizers achieved its highest ever quarterly share of 50.1%, up 4.2 percentage points versus year ago. And ARM & HAMMER baking soda achieved its highest ever quarterly net sales in the first quarter. All in all, a great quarter for the ARM & HAMMER megabrand, which is our largest mega brand with over $1 billion in annual sales. Next, the OxiClean megabrand had a strong overall quarter. The brand's total dollar consumption was up over 20% driven by the new OxiClean liquid laundry detergent line, which was launched in the first quarter of 2014. OxiClean's share of the $1 billion stain product category, its original category, declined by two-tenths to 44.9%. But this is still greater than the combined share of the next three brands, which are sold by three companies many times larger than Church & Dwight. Our third megabrand, the Trojan brand, had a mixed quarter. The Trojan condom business achieved its highest quarterly share in the past five years. It's 76.6%, up 0.2 percentage points versus a year ago. In the total condom category, the top 14 SKUs all belong to the Trojan brand and 26 of the top 30 SKUs are also Trojan SKUs. Other forms of the Trojan megabrand also had a strong quarter. The Trojan Vibrations line of products achieved an 8.3% increase in dollar consumption and recorded its second highest dollar sales quarter ever. Our Vibrations line now has the top three SKUs and six of the top 10 SKUs in the category. The Trojan lubricant line, first launched in February of 2013, has now achieved an 8.5% share of the category, making it the number three selling brand in the lubricants category. This new product line continues to show share potential as revealed by the 11.3% dollar share that it achieved during the week of Valentine's Day, an all-time high for the brand. Last but not the least is our newest megabrand, the gummy vitamin business, which we bought in October 2012. This business consists of two brands, Li'l Critters for kid's gummy vitamins and Vitafusion for adult gummy vitamins. Our gummy vitamins business had a solid first quarter despite supply constraints, which we believe will be shortly resolved by the startup of the new production line in our York manufacturing facility, which we expect will increase our production capacity by about 75%. First, there was great news concerning the growth of the total vitamin, mineral and supplement category. As you may recall, this category has been one of the fastest and most consistently growing categories in all of consumer packaged goods for many years. Then, in the fourth quarter of 2013, a study was released which question the positive health benefits of taking vitamins. This negative news led to several quarters of flat to declining consumption of vitamins. However, the category started to rebound in the second quarter of 2014. And now, it's starting to demonstrate more robust growth as reflected in the 4.3% growth achieved in the first quarter of 2015. Second, our branded vitamin business grew a stellar consumption by 7% in the first quarter, driven by a 13% consumption growth of our adult Vitafusion brand. Vitafusion continues to be the number one adult gummy vitamin with more than double the sales of the number two gummy brand. Third, our Li'l Critters kid vitamin business is struggling right now as dollar consumption fell about 10% in the first quarter, driven by some aggressive competitive pricing and new products. We expect to reverse these trends by the end of 2015, driven by some new products that will be launching. Overall, a very solid quarter for our four megabrands, with three of the four achieving share growth and, in some cases, new record shares driven by our product innovations. I'll finish off our portion of the call today with a few words on our outlook for the year, just to reiterate what Matt just told you. As stated in the press release, as a result of our strong first quarter results, we are raising our 2015 guidance for organic sales growth from 2% to 3% to 3%. And we're raising our expectations for gross margin improvement from 25 basis points to 25 to 35 basis points, and we're maintaining our earnings growth target of 7% to 9% despite an increased drag from currency from 2.5% to 3%. We feel confident in delivering these targets, which are in the top quartile of EPS projections in our industry, consistent with our historical performance. It's just too early in the year to get even more bullish, given the ongoing uncertainty about the worldwide economy, currency rates and competitive activity. The achievement of our targets will be driven by our resilient portfolio of value and premium products, the launch of innovative new products across every one of our major categories, aggressive productivity programs and tight management of overhead costs. I also want to assure you that we are aggressively pursuing acquisitions and have significant financial firepower to make them. As you know, we have a great track record of making highly accretive acquisitions, because we are very selective about the types of businesses we acquire and we're very aggressive on how we integrate them into our existing business. That ends our presentation. And I will open the call to questions that you may have, which Matt and I will do our best to answer. Operator, please go ahead.